Associations between genetic HPV 16 diversity 1

and cervical cancer prognosis

0	
4	
5	Patrícia Patury ¹ , Fábio B. Russomano ² , Luiz F.L. Martins ³ , Miguel Angelo Martins
6	Moreira⁴ , Raquel B.M. Carvalho⁵ , Nádia R. C. Kappaun ⁶ , Liz Maria de Almeida³
7	
8	
9 10 11 12	1 Gynecologic Oncology Department, Brazilian National Cancer Institute (INCA), Ministry of Health, Rio de Janeiro, Rio de Janeiro, Brazil and Departament of Clinical and Surgical Care of Women, National Institute of Women, Children and Adolescents Health Fernandes Figueira, Rio de Janeiro, Rio de Janeiro, Brazil
13 14 15 16 17	2 Departament of Clinical and Surgical Care of Women, National Institute of Women, Children and Adolescents Health Fernandes Figueira, Rio de Janeiro, Rio de Janeiro, Brazil
17 18 19	3 Division of Surveillance and Situation Analysis, Brazilian National Cancer Institute (INCA), Ministry of Health, Rio de Janeiro, Rio de Janeiro, Brazil
20 21 22	4 Genetics Program, Brazilian National Cancer Institute (INCA), Ministry of Health, Rio de Janeiro, Rio de Janeiro, Brazil
23 24 25 26 27	5 Departament of Physiotherapy, Brazilian National Cancer Institute (INCA), Ministry of Health, Rio de Janeiro, Rio de Janeiro, Brazil and Departament of Female Endocrinology, National Institute of Women, Children and Adolescents Health Fernandes Figueira, Rio de Janeiro, Rio de Janeiro, Brazil
28 29 30 31	6 Departament of Physiotherapy, Brazilian National Cancer Institute (INCA), Ministry of Health, Rio de Janeiro, Rio de Janeiro, Brazil
32	E-mail: patricia.patury1@gmail.com (PP)
33	
34	
35	Abstract

Introduction: Cervical cancer (CC) arises as a result of chronic and persistent 36

female genitalia infection by different oncogenic human papillomaviruses (HPV). NOTE: This preprint reports new research that has not been certified by peer review and should hot be used to guide clinical practice. 37

2

The incidence of this disease is still high in developing countries such as Brazil, 38 39 where the diagnosis is often made in advanced stages. HPV 16 is the most common type of CC worldwide. Studies concerning the association of different 40 HPV 16 lineages with overall and disease-free CC survival rates can contribute 41 to further understanding the behavior of different HPV 16 lineages concerning the 42 prognosis of CC cases. Objective: Assess the CC prognosis of patients treated 43 in a Brazilian institution with regard to HPV16 strains. Methods: Data were 44 obtained from a prospective cohort of 334 CC patients recruited between July 45 2011 and March 2014 and treated at the Brazilian National Cancer Institute 46 47 (INCA), in Rio de Janeiro, Brazil. HPV 16 lineages were identified in tumor tissue samples. Genetic HPV 16 diversity comprised 218 cases of lineage A, 10 of 48 lineage B, 10 of lineage C and 96 of lineage D. In addition to HPV 16 lineages, 49 50 age, histopathological type, staging, and treatment completion were evaluated regarding CC prognosis. Results: Median patient age was 48 years old. The 51 most common histopathological type was squamous cell carcinoma (82.3%), 52 followed by adenocarcinoma. Locally advanced disease staging was the most 53 54 frequently detected, represented by similar stage II and III percentages (36.2%) 55 and 37.7%), followed by initial stage I (19.2%) and stage IV presenting distant disease (6.9%). Only 187 patients completed CC treatment. Age, histological 56 type, staging, and treatment completion were associated with a higher risk of 57 58 death, which was not observed for the HPV 16 lineage variable. With regard to age, each one year of life increase led to about a 1% increase in risk of death. 59 Other histopathological types (poorly differentiated carcinoma, adenosquamous, 60 neuroendocrine and sarcoma) were associated with a higher risk of death 61 compared to adenocarcinoma. Squamous cell carcinoma also represented a 62

higher risk of death compared to adenocarcinoma, albeit non-statistically
significant. Patients diagnosed in advanced stages exhibited a higher risk of
death, and those who did not complete treatment exhibited an over 2-fold
increased risk of death. **Conclusion:** This study found no associations between
HPV 16 lineages A, B, C and D and CC prognosis.

68

69 **Keywords**: Cervical neoplasia, HPV 16, HPV 16 strains, prognosis, survival.

70

71 Introduction

Cervical cancer (CC) is still a serious public health problem, especially in less developed countries, despite being considered a preventable disease through vaccination, screening, and treatment of precursor lesions. In countries with an opportunistic screening system, such as Brazil, or in those without public screening programs, CC diagnoses are often made when women already present advanced symptoms, compromising survival and quality of life [1].

Cervical cancer is the third most common cancer in Brazil among women excluding non-melanoma skin cancer. The number of new CC cases expected in Brazil is of 17,010 for each year of the 2023-2025 triennium, with a mortality rate of 6,627 deaths noted for 2021 [2, 3].

Different CC evolution processes in women with similar prognostic factors have not yet been fully clarified. Age, staging at diagnosis, lymphovascular space invasion, histopathological type and the presence of anemia are classically associated to CC prognoses [1, 4]. The prognostic value of oncogenic human papillomaviruses (HPV) DNA detection in tumors has not yet been established and studies with this objective have reported conflicting results. Some authors

postulate that the presence of oncogenic HPV may be a useful CC prognosis
marker prior to treatment, as this makes the precursor lesion progression more
aggressive [5, 6]. Others, however, state that different types of oncogenic HPV
have no prognostic value in CC cases [7, 8].

HPV 16 is the HPV most commonly associated with CC, and its four lineages were initially named according to the geographic region where they were most frequently identified, associated to local ethnicities [9, 10]. Since 2013, however, they have been termed A, B, C and D [11-14]. Each HPV 16 lineage (A, B, C and D) is subdivided into sublineages, as follows: A1-A3 (European and Asian lineages), A4 (Asian lineage); B1-B4 (African lineage 1); C1-C4 (African lineage 2); D1-D3 (North American and Asian-American lineages) [9, 10].

Some evidence suggests that different HPV16 lineages may present different pathogenicities, and some of them are associated with a greater risk of developing CC than others [15]. Certain authors have demonstrated that lineages B, C and D play a more important role in the progression of precursor cervix lesions in the invasive CC form when compared to lineage A [9, 16, 17]. Other studies, however, have suggested that the D lineage, in particular, is highly associated with viral infection persistence and progression to CC [18,1 9, 20].

Regarding the prognostic value of different HPV16 lineages and sublineages in CC cases, Tornesello et al. [21] suggested that the AA (Asian-American) lineage was associated to more aggressive CC behavior. Another study evaluated 301 *in situ* cases and 727 CC cases and reported a higher frequency of HPV 16 D3 and A4 in CC cases and lower disease-free survival rates in women infected with the HPV 16 B lineage compared to lineages A, C and D [22]. In another assessment, Zuna et al. [23] reported more advanced

stages (II-IV) and lower survival rates in women infected with the European HPV

114 16 lineage when assessing 155 CC patients.

In view of these contradictions and the possibility that differences may be associated with population characteristics or influenced by treatment strategies, this study aimed to assess whether the HPV 16 lineages present in CC cases treated at the Brazilian National Cancer Institute (INCA) in Rio de Janeiro, Brazil, influence CC prognosis regarding overall survival and progression-free survival.

121 Methods

122 **Patients**

This prospective cohort study took place at a specialized gynecological 123 oncology center in Brazil from July 2011 to March 2014. It selected women aged 124 18 years or older, diagnosed with FIGO-2009 IB1 or higher cervical cancer (CC), 125 and excluded patients who had undergone previous cancer treatment [17, 24]. 126 Over the course of a five-year duration, all participants were monitored, with their 127 clinical data collected until January of 2022. All participants provided written 128 informed consent prior to participation. Ethical approval for the study was 129 130 provided by the Human Research Ethics Committee at the oncology center. Nine hundred and sixty-eight women with a histopathological diagnosis of 131 CC were included. All were 18 years old or older and had not undergone previous 132

132 CC were included. All were its years on or order and had not undergone previous
 133 oncological CC treatment. The HPV types and lineages in positive HPV16 cases
 134 were identified by tumor tissue biopsies obtained at the first consultation for 594
 135 (61.4%) patients. New samples were not obtained for the remaining cases due to
 136 technical difficulties, poor clinical patient conditions or refusal to undergo the

procedure. The samples were immediately stored in RNA-Later at -80°C and
deposited in the National Cancer Institute Tumor Bank.

139

140 DNA isolation and identification of HPV16 genotypes

141 and lineages

Total DNA was isolated from the obtained biopsies using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) and eluted in 200 microliters (μ L) of AE buffer and stored at – 80°C. After isolation, the presence of viral DNA was detected by polymerase chain reactions (PCR) with a set of PGMY09/11 primers [25]. When DNA was not detected by this technique, a nested PCR was performed employing the GP5p/GP6p primers [17, 26].

The amplified PCR products were purified using the GFX PCR and DNA 148 149 Band Purification kit (GE Healthcare), sequenced with the Big Dye Terminator 150 v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) and analyzed using an ABI Prism. 3130XL Genetic Analyzer (Applied Biosystems). All 151 152 sequences were edited and analyzed using the 4Peaks Software (Nucleobytes, Amsterdam, Netherlands). HPV genotypes were identified using the Basic Local 153 Alignment Search Tool (BLASTn, http://blast.ncbi.nlm.nih.gov/) [17]. The biopsies 154 presenting HPV16 genotypes (n=392) were submitted to PCR for amplification of 155 156 the viral genomic regions E6 and LCR, followed by DNA sequencing. This 157 allowed the identification of different haplotypes, and HPV16 lineages and were reported previously in Vidal et al. (2016) [27]. HPV16 lineages were identified in 158 334 samples Fig 1. 159

Fig 1. Flowchart depicting patient inclusion and types of detected HPV. Fig
1. (INCA, 2011-2014).

162

163 Socioeconomic data

A questionnaire was applied to obtain educational, environmental, and socioeconomic characteristics of all enrolled patients. Clinical information concerning treatment and follow-up regarding patients infected with HPV16 was obtained from both physical and electronic records.

168

169 Statistical analyses

Crude and adjusted prevalence ratios and their respective 95% confidence intervals (95% CI) were calculated by means of the Poisson regression model with variations to determine associations between HPV 16 lineages and other variables [28, 29]. A multinominal logistic regression model was applied concerning histological type, due to three histological categories. Models presenting p values < 0.05 were considered significant.

Kaplan-Meyer curves were used in a univariate and stratified manner for confounding variables for the survival analyses. A semiparametric proportional risk model (Cox model) was used for the multivariate analyses. Two Schoenfeld residuals were analyzed to verify model validity, and associations were considered significant when p < 0.05.

Overall survival rates were calculated setting the survival time as the interval between the data of histopathological revision of the biopsy for diagnosis confirmation and the date of death or last follow-up. Recurrence or recurrencefree survival times were defined in months, considering the interval between the date of the end of the treatment and the date of the recurrence or the date of the last consultation with no CC signs. Patients presenting disease progression

throughout the treatment or at treatment end were not included in the disease-free survival analysis.

All procedures were approved by the INCA Ethics and Research Committee (number 156/10, on 02/25/2011) and a specific amendment for this study (CAAE: 53398416.0.0000.5274, on 03/01/2016) and all the patients signed a consent form.

193

194 **Results**

Patient and tumor characteristics are depicted in Table 1. Median patient
age was 48 years old. Most women carried lineages A (65.3%) and D (28.7%),
while lineage B was detected in 3% of all cases and lineage C, in another 3%.

The most common histopathological type was squamous cell carcinoma (82.3%), followed by adenocarcinoma (12.9%). Stages II and III were the most common (36.2% and 37.7%), followed by stage I (19.2%) and IV (6.9%). Only 187 women completed treatment. Regarding treatment results, about 1/3 of the patients exhibited disease persistence (31.4%), most displayed disease remission and did not relapse (65%) and 192 died during the follow-up period Table 1.

205

Table 1. Description of the study population (n = 334).

Characteristics	n	%
Sociodemographic		
Age (years)		
Up to 39	96	28.7
40 to 49	93	27.8

50 to 64	106	31.7
65 and over	39	11.7
Years of study		
None	19	5.7
1 to 3	70	21.0
4 to 7	108	32.3
8 to 10	82	24.6
11 and over	55	16.5
Marital status		
Single	28	8.4
Married	184	55.1
Divorced	71	21.3
Widow	51	15.3
Skin color		
White	108	32.3
Brown	178	53.3
Black	46	13.8
Yellow	2	0.6
HPV 16 genotyping (detected lineages)		
A	218	65.3
В	10	3.0
C	10	3.0
D	96	28.7
Tumor and treatment features		
Histological Type		
Squamous cell carcinoma	275	82.3
Adenocarcinoma	43	12.9

Others ¹	16	4.8
Staging		
I	64	19.2
II	121	36.2
III	126	37.7
IV	23	6.9
Treatment completion		
Yes	187	56.0
No	147	44.0
Outcome		
Persistence		
Yes	105	31.4
No	229	68.6
No data		
Relapse (of the 229 patients with no dise	ase	
persistence)		
Yes	80	34.9
No	149	65.1
Death		
Yes	192	57.5
No	142	42.5
Death due to cervical cancer		
	174	52.1
Yes		

Overall Survival

The median follow-up time for the enrolled patients was of 35.9 months (1Q = 12.6 months; 2Q = 36.3 months and 3Q = 66 months), and the median overall survival time was of 40.3 months ($CI_{95\%}$: 29.9 – 49.8). Kaplan-Meyer curves according to each HPV 16 lineage are displayed in

Kaplan-Meyer curves according to each HPV 16 lineage are displayed in Fig 2. The median overall survival was of 35.9 months among patients carrying lineage A and 45.9 months among those carrying lineage D. No estimated median was determined for the B/C group, as the survival curve was influenced by sample size. No statistically significant difference between the survival curves (p = 0.21; Log Rank test) was observed.

220

Fig 2 - Five-year overall survival curve of cervical cancer patients since the beginning of the treatment according to HPV 16 lineage*.

Fig 2. Lineage A = 218 cases, B = 10 cases, C = 10 cases, D = 96 cases. *HPV 16 lineages B and C were grouped due to their low frequency.

225

Table 2 indicates risk of patient death according to the study variables. Age, histological type, treatment completion and staging were associated with a higher risk of death, while HPV 16 lineage was not. Concerning age, about a 1% increase in the risk of death was noted for each one year of life increase.

characterized 230 Tumors as other histopathological types (poorly 231 differentiated carcinoma, adenosquamous, neuroendocrine and sarcoma) were associated to a higher risk of death compared to adenocarcinoma (HR: 2.47) 232 233 (95% CI 1.17 - 5.19). Patients presenting squamous cell carcinomas also exhibited a higher risk of death than those presenting adenocarcimomas, 234 235 although non-statistically significant Table 2.

Women diagnosed in advanced stages displayed a higher risk of death and those who did not complete treatment presented a more than two-fold increased risk of death (HR: 2.69 (2.00 - 3.61)) Table 2.

	-	Crude HR	P value	
Characteristic	n	(CI 95%)		
HPV 16 lineage				
A	218	1.18 (0.85 - 1.64)	0.32	
B/C	20	0.67 (0.32 - 1.41)	0.29	
D	96	1	-	
Age (years)		1.01 (1.00 - 1.02)	0.02	
Histological type				
Squamous cell carcinoma	275	1.51 (0.94 - 2.43)	0.09	
Adenocarcinoma	43	1	-	
Others	16	2.47 (1.17 - 5.19)	0.02	
Staging				
l or ll	185	1	-	
III or IV	149	2.69 (2.00 - 3.61)	< 0.001	
Treatment completion				
Yes	187	1		
No	147	4.06 (3.00 - 5.48)	< 0.001	

Table 2. Overall risk of death in patients with cervical cancer (n = 334)

240 HR: hazard ratio.

241

The staging, histological type and treatment completion data distribution suggest an association between intermediate variables and HPV 16 lineages, which was not observed for age. Considering the possibility that different HPV 16

lineages could be associated with variables that could lead to worse CC
prognoses, prevalence ratios between HPV 16 lineages and other variables
explaining worse prognosis were calculated Table 3. The association between
HPV 16 lineages, staging and treatment completion reached borderline
significance (p=0.07).

250

Table 3. Prevalence ratios between HPV 16 lineages and explanatory

252	variables	for	worse	prognosis
-----	-----------	-----	-------	-----------

	Advanced staging ¹		Histological	type²	Did not finish treatment	
Characteristic	C Prevalence ratio*	Prevalence ratio* p value		p value	Prevalence ratio*	p value
	(CI 95%)		(CI 95%)		(CI 95%)	
HPV 10	5		I		1	<u> </u>
lineage						
А	1.30 (0.97 - 1.74)	0.07	0.70 (0.35 - 1.38)	0.30	1.31 (0.98 - 1.75)	0.07
B/C	0.82 (0.40 - 1.67)	0.54	1.86 (0.52 - 6.73)	0.34	0.80 (0.39 - 1.64)	0.54
D	1				1	-

253 ¹ – Staging III and IV

² - Histological type (Squamous cell carcinoma, Adenocarcinoma, others); using the multiple
 logistic regression model

256

257 Disease-Free Survival

Up to 75% of all patients exhibited a disease-free timeframe lower than 259 23.9 months. The Kaplan-Meyer disease-free survival curves according to HPV 260 16 lineage are presented in Fig 3. The third survival quartile was of 23.5 months 261 among patients carrying lineage A, 31.1 for patients carrying the B/C lineages

and 24.9 months for those carrying lineage D. No estimated median was 262 263 calculated for group B/C due to the number of patients carrying this lineage. No 264 statistically significant difference between survival curves was noted when applying the log-rank test (p = 0.43). 265 266 Fig 3 - Disease-free survival curve in 5 years of patients with cervical cancer 267 since the end of treatment according to HPV 16 lineage*. 268 Fig 3. *Patients who did not exhibit persistent cervical cancer after 269 treatment. *HPV 16 lineages B and C were grouped due to their low 270 frequency. 271 272 Staging was the only variable significantly associated with the risk of CC 273

recurrence, expressed by risk ratios. In this case, women presenting advanced
staging exhibited a HR of 1.83 (95%CI 1.17 - 2.87) compared to those presenting
early staging Table 4.

277

Table 4. Risk of cervical cancer recurrence (n = 229*).

Characteristic	n	Crude HR [†]	P value	
		(CI 95%)	, value	
HPV 16 lineage				
Α	218	0.77 (0.48 - 1.23)	0.28	
B/C	20	0.35 (0.13 - 1.00)	0.3	
D	96	1	-	
Age (years)		1.00 (0.99 - 1.02)	0.59	
Histological type				

medRxiv preprint doi: https://doi.org/10.1101/2024.08.02.24311429; this version posted August 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Squamous cell carcinoma 275 0.70 (0.41 – 1.18) 0.18 Adenocarcinoma 43 1 _ Others 0.24(0.03 - 1.83)16 0.17 Staging l or ll 185 1 III or IV 149 1.83 (1.17 - 2.87) 0.008 **Treatment completion** Yes 187 1 No 147 1.14 (0.68 – 1.92) 0.61 279 * Patients who did not exhibit persistence post-treatment cervical cancer,

280 [†]HR = hazard ratio

281

282 **Discussion**

This study aimed to assess the influence of HPV 16 strains on CC prognosis. In this sense, only age, histopathological type, disease staging, and treatment completion were associated with a higher risk of death.

No associations between HPV 16 lineages and CC prognosis were noted, although different prevalences of each were detected according to stage, with no confounding effect demonstrated between these variables Table 3. The low frequencies of lineages B and C may have contributed to the lack of statistically significant associations noted herein. The most frequently detected lineage was the A (Asian-European) lineage, in contrast to that reported by Tornesello et al. [30] (Asian-American), which was termed lineage D in this study. As suggested

by Tornesello et al. [30], lineage D exhibited more aggressive behavior in CC
cases [30].

Although no significant CC prognosis differences were detected in relation 295 to HPV 16 lineages, other authors have noted this association. Zuna et al. [31], 296 297 for example, reported lower survival rates in women carrying the European lineage. In our study, the better survival rates observed for patients carrying non-298 299 European lineages (B, C and D) were partially mediated by initial staging at diagnosis, suggesting that this lineage is associated to less aggressive tumor 300 301 behavior compared to the European lineage. In another study, Rader et al. [32] 302 reported lower disease-free survival rates in patients carrying the HPV16 B 303 lineage.

The median age of CC patients in the present study was 48 years old, and a 1% increase in the risk of death was noted with each increasing year. This finding is in agreement with studies that have demonstrated age as an independent CC prognostic factor [33-38].

Squamous cell carcinoma was the most common histopathological type detected in the present study, representing 82.3% of all cases Table 1, in line with other literature reports [1]. The "others" histopathological category defined herein (poorly differentiated carcinoma, adenosquamous, neuroendocrine and sarcoma) presented a higher risk of death in relation to adenocarcinoma Table 2. These tumors exhibit a more aggressive clinical evolution and are generally diagnosed at more advanced stages [39, 40].

Contrary to other authors, who report worse prognosis for adenocarcinoma cases [41-44], a higher risk of death for patients presenting squamous cell

carcinoma was observed herein, albeit not statistically significant. This may be
due to the fact that most adenocarcinoma cases were detected in stage I.

319 Staging was the only significant variable regarding CC recurrence risk, in agreement with other authors [1, 45]. Furthermore, patients exhibited a 4-fold 320 321 increase concerning risk of death when they did not complete the treatment. Most women unable to complete treatment presented advanced CC stages and 322 323 exhibited associated comorbidities, such as anemia and kidney failure, making it 324 impossible to complete initial therapeutic plans. Other authors have associated treatment completion and other variables to age, reporting that CC patients aged 325 326 70 or over exhibit a higher rate of less aggressive treatment or were unable to 327 receive treatment at all, although they do not mention why no treatment or incomplete treatment took place [33]. 328

An unequal incomplete treatment distribution according to HPV 16 lineage Table 4 was noted in the present study, where just over half of the patients carrying lineages A and D did not complete the treatment, while 80% of those carrying the B/C lineages did so. This may have been influenced by lineage staging distribution.

Although no significant association between HPV 16 strains and CC prognosis was observed, few studies have assessed this issue to date. This association may not have been detected in the present study due to the limited sample size for certain HPV 16 lineages. Studies encompassing larger sample sizes will be able elucidate this issue and guide new treatment protocols and better information for patients if associations are demonstrated.

340

341 Conclusion

No statistically significant associations between HPV 16 lineages and CC 342 prognosis were observed herein. Age, poorly differentiated carcinoma, 343 neuroendocrine and sarcoma 344 adenosquamous, histopathological types, advanced staging and incomplete treatment were associated with worse CC 345 prognoses. Considering the sample size limitations of some of HPV16 strains in 346 this study, their influence on CC prognosis cannot be disregarded, and further 347 studies in this regard may contribute to elucidate this issue. 348

349

350 Acknowledgments

We thank all the women treated at INCA in Rio de Janeiro, for allowing this project to be carried out. We also thank the interdisciplinary teams that participated in the treatment and follow up of these women.

354

355 **References**

- Marth C, Landoni S, Mahner S, et al. Cervical Cancer: ESMO Clinical 357 1. Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann 358 359 Oncol [Internet]. 2017 [citado em: 23 de novembro de 2021]; 28(suppl 4):iv72-iv83. Erratum in: Ann Oncol. 2018 1;29 (Suppl 4): iv262. 360 361 Disponível em: https://pubmed.ncbi.nlm.nih.gov/28881916/. Doi: 10.1093/annonc/mdx220. PMID: 28881916. 362
- BRASIL. Ministério da Saúde. INCA Instituto Nacional de Câncer José
 Alencar Gomes da Silva [Internet]. Estatísticas de câncer. [Publicado
 em 23 de junho de 2022, atualizado em 24 de novembro de 2022]. [citado
 em: 30 de novembro de 2022]. Disponível em: https://www.gov.br/inca/pt br/assuntos/cancer/numeros.
- BRASIL. Ministério da Saúde. INCA Instituto Nacional de Câncer José
 Alencar Gomes da Silva. Detecção Precoce. [Internet]. 2022 [citado em:

270		20 de novembre de 20221 Dubligade em 2022 Dianonível em:
370		bttps://www.gov.br/ippo/pt.br/popurtos/goster.c.profissional.do
3/1		nttps://www.gov.br/inca/pt-br/assuntos/gestor-e-profissional-de-
372		saude/controle-do-cancer-do-colo-do-utero/acoes/deteccao-precoce
373	4.	Koulis TA, Kornaga EN, Banerjee R, et al. Anemia, Leukocytosis and
374		Thrombocytosis as Prognostic Factors in Patients with Cervical
375		Cancer Treated with Radical Chemoradiotherapy: A Retrospective
376		Cohort Study. Clin Transl Radiat Oncol [Internet]. 2017 [citado em: 09
377		de julho de 2022]; 4;51-56. Disponível em:
378		https://pubmed.ncbi.nlm.nih.gov/29594208/. Doi:
379		10.1016/j.ctro.2017.05.001. PMID: 29594208; PMCID: PMC5833917.
380	5.	Li Ping, Tan Yue, Zhu Li-Xia, et al. Prognostic Value of HPV DNA Status
381		in Cervical Cancer Before Treatment: A Systematic Review and Meta-
382		Analysis. Oncotarget [Internet]. 2017 [citado em: 04 de setembro de
383		2021]; 8(39):66352–66359. Disponível em:
384		https://pubmed.ncbi.nlm.nih.gov/29029517/. Doi:
385		10.18632/oncotarget.18558. PMID: 29029517; PMCID: PMC5630417.
386	6.	Chong GO, Lee YH, Soo Han H, et al. Prognostic Value of Pre-
387		Treatment Human Papilloma Virus DNA Status in Cervical Cancer.
388		Gynecologic Oncology [Internet]. 2017 [citado em: 02 de junho de 2022];
389		p97-102. Disponível em: https://pubmed.ncbi.nlm.nih.gov/29153540/. Doi:
390		10.1016/j.ygyno.2017.11.003. PMID: 29153540.
391	7.	Ikenberg H, Sauerbrei W, Schottmüller U, et al. Human Papillomavirus
392		Dna in Cervical Carcinoma—Correlation with Clinical Data and
393		Influence on Prognosis. Int. J. Cancer [Internet]. 1994 [citado em: 05 de
394		agosto de 2022]; 59 (3)322–326. Disponível em:
395		https://europepmc.org/article/MED/7927936. Doil:
396		10.1002/ijc.2910590306. PMID: 7927936.
397	8.	Füle T. Csapó Z. Máthé M. et al. Prognostic Significance of High-Risk
398		Hov Status in Advanced Cervical Cancers and Pelvic Lymph Nodes.
399		Gynecol Oncol [Internet] 2006 [citado em: 09 de outubro de 2022]: 100
400		(3) 570-578 Enub 2005 Dispon(vel em:
/01		https://pubmed.ncbi.plm.nih.gov/16325245/
402		10 1016/i vovpo 2005 00 010 PMID: 16225245
402		10.1010/j.ygyn0.2003.03.013. FWID. 10323243.

9. Clifford GM, Tenet V, Georges D, et al. Human papillomavirus 16 sublineage dispersal and cervical cancer risk worldwide: whole viral
genome sequences from 7116 HPV16- positive women. Papillomavirus
Res [Internet]. 2019 [citado em: 16 de setembro de 2021]; 7:67-74.
Disponível em: <u>https://pubmed.ncbi.nlm.nih.gov/30738204/</u>. Doi:
10.1016/j.pvr.2019.02.001. PMID: 30738204; PMCID: PMC6374642.

- 10. Mirabello L, Clarke MA, Nelson CW, et al. The Intersection of HPV 409 Epidemiology, Genomics and Mechanistic Studies of HPV-Mediated 410 Carcinogenesis. Viruses [Internet]. 2018 [citado em: 09 de outubro de 411 10(2):80. 412 2022]; Disponível em: https://pubmed.ncbi.nlm.nih.gov/29438321/. 413 Doi: 10.3390/v10020080. PMID: 29438321; PMCID: PMC5850387. 414
- 415 11. Ho L, Chan S, Burk R, et al. The Genetic Drift of Human Papillomavirus
 416 Type 16 Is a Means of Reconstructing Prehistoric Viral Spread and
 417 the Movement of Ancient Human Populations. J Virol [Internet]. 1993
 418 [citado em: 08 de abril de 2022]; 16:6413–6423. Disponível em:
 419 https://journals.asm.org/doi/10.1128/jvi.67.11.6413-6423.1993.
- 12. Ong CK, Chan SY, Campo MS, et al. Evolution of Human 420 Papillomavirus Type 18: An Ancient Phylogenetic Root in Africa and 421 Intratype Diversity Reflect Coevolution with Human Ethnic Groups. J 422 Virol [Internet]. 1993 [citado em: 08 de abril de 2022]; 67(11):6424–6431. 423 Disponível https://pubmed.ncbi.nlm.nih.gov/8411344/. 424 em: Doi: 10.1128/JVI.67.11.6424-6431.1993. PMID: PMCID: 425 8411344: PMC238077. 426

13. Yamada T, Manos MM, Peto J, et al. Human Papillomavirus Type 16 427 Sequence Variation in Cervical Cancers: A Worldwide Perspective. J 428 Virol [Internet]. 1997 [citado em: 03 de março de 2022]; 71(3):2463-72. 429 https://pubmed.ncbi.nlm.nih.gov/9032384/. 430 Disponível em: Doi: 10.1128/JVI.71.3.2463-2472.1997. PMID: 9032384; PMCID: 431 PMC191357.71:2463-2472. 432

433 14. Burk RD, Terai M, Gravitt PE, et al. Distribution of human
 434 papillomavirus types 16 and 18 variants in squamous cell carcinomas
 435 and adenocarcinomas of the cervix. Cancer Res [Internet]. 2003

436 [citado em: 09 de abril de 2022]; 63(21):7215–20. Disponível em:
 437 <u>https://pubmed.ncbi.nlm.nih.gov/14612516</u>.

- 15. Margolis B, Cagle-Colon K, Chen L, et al. Prognostic Significance of 438 Lymphovascular Space Invasion for Stage Ia1 and Ia2 Cervical 439 Cancer. Int J Gynecol Cancer [Internet]. 2020 [citado em: 07 de março 440 30:735-743. de 2022]; Disponível 441 em: https://pubmed.ncbi.nlm.nih.gov/32179697/. Doi: 10.1136/ijgc-2019-442 000849. PMID: 32179697. 443
- 16. Chen JL, Huang C-Y, Huang Y-S, et al. Differential clinical 444 characteristics, treatment response and prognosis of locally 445 446 advanced adenocarcinoma/adenosquamous carcinoma and cell carcinoma of cervix treated with definitive 447 squamous 448 radiotherapy. Acta Obstet Gynecol Scand [Internet]. 2014 [citado em: 01 de marco de 20231: 93(7):661-8. Disponível 449 em: 450 https://pubmed.ncbi.nlm.nih.gov/24666257/. Doi: 10.1111/aogs.12383. PMID: 24666257. 451
- Vidal JPCB, Felix SP, Chaves CBP, et al. Genetic Diversity of HPV16
 and HPV18 in Brazilian Patients with Invasive Cervical Cancer. J Med
 Virol [Internet]. 2016 [citado em: 14 de março de 2023]; 88(7):1279-87.
 Disponível em: <u>https://pubmed.ncbi.nlm.nih.gov/26694554/</u>. Doi:
 10.1002/jmv.24458. PMID: 26694554.
- 18. Schiffman M, Rodriguez AC, Chen Z, et al. A population-based 457 prospective study of carcinogenic human papillomavirus variant 458 lineages, viral persistence, and cervical neoplasia. Cancer Res 459 [Internet]. 2010 [citado em: 30 de abril de 2023]; 70(8):3159-69. 460 Disponível em: https://pubmed.ncbi.nlm.nih.gov/20354192/. Doi: 461 10.1158/0008-5472.CAN-09-4179. PMID: 20354192; PMCID: 462 PMC2855741. 463
- 464 19. Berumen J, Ordoñez RM, Lazcano E, et al. Asian-American variants of
 465 human papillomavirus 16 and risk for cervical cancer: a case-control
 466 study. J Natl Cancer Inst [Internet]. 2001 [citado em:02 de dezembro de
 467 2022]; 5;93(17):1325-30. Disponível em:
 468 https://pubmed.ncbi.nlm.nih.gov/11535707. Doi: 10.1093/jnci/93.17.1325.
 469 PMID: 11535707.

20. Xi LF, Koutsky LA, Hildesheim A, et al. Risk for high-grade cervical
intraepithelial neoplasia associated with variants of human
papillomavirus types 16 and 18. Cancer Epidemiol Biomarkers Prev
[Internet]. 2007 [citado em: 05 de dezembro de 2022]; 16(1):4-10.
Disponível em: https://pubmed.ncbi.nlm.nih.gov/17220325/. Doi:
10.1158/1055-9965.EPI-06-0670. PMID: 17220325.

- Tornesello ML, Losito S, Benincasa G, et al. Human papillomavirus
 (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix. Gynecol Oncol [Internet].
 2011 [citado em: 10 de dezembro de 2022]; 121(1):32-42. Disponível em:
 https://pubmed.ncbi.nlm.nih.gov/21211829/.
- 481 10.1016/j.ygyno.2010.12.005. PMID: 21211829.
- 22. Rader JS, Tsaih SW, Fullin D, et al. Genetic variations in human
 papillomavirus and cervical cancer outcomes. Int J Cancer [Internet].
 2019 [citado em: 03 de janeiro de 2023]; 144(9): 2206–2214. Disponível
 em: <u>https://pubmed.ncbi.nlm.nih.gov/30515767/</u>. Doi:10.1002/ijc.32038.
 PMID: 30515767; PMCID: PMC6450540.
- 23. Zuna RE, Tuller E, Wentzensen N, et al. HPV16 variant lineage, clinical
 stage, and survival in women with invasive cervical cancer. Infect
 Agents Cancer [Internet]. 2011 [citado em: 23 de abril de 2023]; 6:19.
 Disponível em: <u>https://doi.org/10.1186/1750-9378-6-19</u>.
- 491 24. de Almeida LM, Martins LFL, Pontes VB, et al. Human Papillomavirus
 492 Genotype Distribution among Cervical Cancer Patients prior to
 493 Brazilian National HPV Immunization Program. J Environ Public Health
 494 [Internet]. 2017 [citado em: 04 de dezembro de 2022]; v. 2017:1645074,
 495 p.9. Disponível em: https://pubmed.ncbi.nlm.nih.gov/28512474/. Doi:
 496 10.1155/2017/1645074. PMID: 28512474; PMCID: PMC5420420.
- 497 25. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of
 498 genital human papillomaviruses. J Clin Microbiol [Internet]. 2000
 499 [citado em: 01 de fevereiro de 2023]; 38:357–361. Disponível em:
 500 <u>https://pubmed.ncbi.nlm.nih.gov/10618116/</u>. Doi: 10.1128/JCM.38.1.357501 361.2000. PMID: 10618116; PMCID: PMC88724.
- 50226. Fuessel Haws AL, He Q, Rady PL, et al. Nested PCR with the503PGMY09/11 and GP5(+)/6(+) primer sets improves detection of HPV

DNA in cervical samples. J Virol Methods [Internet]. 2004 [citado em: 13 504 de 505 de fevereiro 2023]; 122:87-93. Disponível em: 506 https://pubmed.ncbi.nlm.nih.gov/15488625/. doi: 10.1016/j.jviromet.2004.08.007. PMID: 15488625. 507 27. Vidal JPCB, Felix SP, Chaves CBP, et al. Genetic Diversity of HPV16 508 and HPV18 in Brazilian Patients with Invasive Cervical Cancer. J Med 509 Virol [Internet]. 2016 [citado em: 14 de março de 2023]; 88(7):1279-87. 510 https://pubmed.ncbi.nlm.nih.gov/26694554/. Disponível em: Doi: 511 10.1002/jmv.24458. PMID: 26694554. 512 28. Zocchetti C, Consonni D, Bertazzi PA. Relationship between prevalence 513 rate ratios and odds ratios in cross-sectional studies. Int J Epidemiol 514 [Internet]. 1997 [citado em: 26 de março de 2023]; 26(1):220-3. 515 516 Disponível em: https://pubmed.ncbi.nlm.nih.gov/9126523/. Doi: 10.1093/ije/26.1.220. PMID: 9126523. 517 518 29. Barros AJ, Hirakata VN. Alternatives for logistics regression in crosssectional studies: an empirical comparison of models that directly 519 520 estimate prevalence ratio. BMC Medical Research Methodology [Internet]. 2003 [citado em: 29 de março de 2023]; 3(21):1-13. Disponível 521 em: https://pubmed.ncbi.nlm.nih.gov/14567763/. Doi: 10.1186/1471-2288-522 3-21. PMCID: PMC521200. PMID: 14567763. 523 30. Tornesello ML, Losito S, Benincasa G, et al. Human papillomavirus 524 (HPV) genotypes and HPV16 variants and risk of adenocarcinoma 525 and squamous cell carcinoma of the cervix. Gynecol Oncol [Internet]. 526 2011 [citado em: 10 de dezembro de 2022]; 121(1):32-42. Disponível em: 527 https://pubmed.ncbi.nlm.nih.gov/21211829/. 528 Doi: 10.1016/j.ygyno.2010.12.005. PMID: 21211829 529 31. Zuna RE, Tuller E, Wentzensen N, et al. HPV16 variant lineage, clinical 530 stage, and survival in women with invasive cervical cancer. Infect 531 Agents Cancer [Internet]. 2011 [citado em: 23 de abril de 2023]; 6:19. 532 Disponível em: https://doi.org/10.1186/1750-9378-6-19. 533 32. Rader JS, Tsaih SW, Fullin D, et al. Genetic variations in human 534 papillomavirus and cervical cancer outcomes. Int J Cancer [Internet]. 535 2019 [citado em: 03 de janeiro de 2023]; 144(9): 2206–2214. Disponível 536

em: https://pubmed.ncbi.nlm.nih.gov/30515767/. Doi:10.1002/ijc.32038. 537 PMID: 30515767; PMCID: PMC6450540. 538 33. Quinn BA, Deng X, Colton A, et al. Increasing Age Predicts Poor 539 **Cervical Cancer Prognosis with Subsequent Effect on Treatment and** 540 Overall Survival. Brachytherapy [Internet]. 2019 [citado em: 19 de 541 2023];18(1):29-37. de Disponível 542 ianeiro em: https://pubmed.ncbi.nlm.nih.gov/30361045/. Doi: 543 10.1016/j.brachy.2018.08.016. PMID: 30361045; PMCID: PMC6338515. 544 34. Barben J, Kamga AM, Dabakuyo-Yonli TS, et al. Cervical cancer in older 545 women: Does age matter? Maturitas [Internet]. 2022 [citado em: 16 de 546 2022]; Epub 547 marco de 158:40-46. 2021. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35241237/. Doi: 548 549 10.1016/j.maturitas.2021.11.011. PMID: 35241237. 35. Knüppel S, STANG A. DAG Program: identifying minimal sufficient 550 551 adjustment sets. Epidemiology [Internet]. 2010 [citado em: 24 de março de 2023]; 21(1):159. Erratum in: Epidemiology. 2010; 21(3):432. 552 Disponível em: https://pubmed.ncbi.nlm.nih.gov/20010223/. Doi: 553 10.1097/EDE.0b013e3181c307ce. PMID: 20010223. 554 36. Sharma C, Deutsch I, Horowitz DP, et al. Patterns of care and treatment 555 outcomes for elderly women with cervical cancer. Cancer [Internet]. 556 2012 [citado em: 22 de fevereiro de 2022]; 15;118(14):3618-26, ISSN 557 2011. 1097-0142. Epub Disponível 558 em: https://pubmed.ncbi.nlm.nih.gov/22038773/. 10.1002/cncr.26589. 559 Doi: PMID: 22038773. 560 37. de Sanjose S, Wheeler CM, Quint WGV, et al. Age-specific occurrence 561 of HPV 16-and HPV 18-related cervical cancer. Cancer Epidemiol 562 Biomarkers Prev [Internet]. 2013 [citado em: 06 de março de 2021]; 563 1313-1318. Disponível em: https://pubmed.ncbi.nlm.nih.gov/23632816/. 564 23632816; 10.1158/1055-9965.EPI-13-0053. PMID: 565 Doi: PMCID: PMC4306595. 566 38. Dale DC. Poor prognosis in elderly patients with cancer: the role of 567 bias and undertreatment. J Support Oncol [Internet]. 2003 [citado em: 568 20 de janeiro de 2023]; 1(4 Suppl 2):11-7. PMID: 15346995. Disponível 569 570 em: https://www.ncbi.nlm.nih.gov/pubmed/15346995. PMID: 15346995.

39. Albores-Saavedra J, Gersell D, Gilks B, et al. Terminology of Endocrine 571 Tumors of The Uterine Cervix: Results of A Workshop Sponsored by 572 The College of American Pathologists And The National Cancer 573 Institute. Arch Pathol Lab Med [Internet]. 1997 [citado em: 15 de junho 574 2022]; 121(1):34-9. 575 de Disponível em: https://pubmed.ncbi.nlm.nih.gov/9111090/. PMID: 9111090. 576

- SS, Sherman ME, Silverberg SG, et al. Pathological 577 40. Wang Characteristics of Cervical Adenocarcinoma in A Multi-Center U.S. 578 579 Based Study. Gynecol Oncol Internet]. 2006 [citado em: 02 de agosto de 2022]; 103(2):541-6. Disponível 580 em: https://pubmed.ncbi.nlm.nih.gov/16697450/. 581 Doi:
- 10.1016/j.ygyno.2006.03.049. PMID: 16697450. 582
- 41. Galic V, Herzog TJ, Lewin SN, et al. Prognostic Significance of 583 Adenocarcinoma Histology in Women with Cervical Cancer. Gynecol 584 585 Oncol [Internet]. 2012 [citado em: 05 de junho de 2022]; 125(2):287-291. https://pubmed.ncbi.nlm.nih.gov/22266551/. Disponível em: Doi: 586 10.1016/j.ygyno.2012.01.012. PMID: 22266551. 587
- 42. Kodama J, Seki N, Nakamura K, et al. **Prognostic Factors in Pathologic** 588 Parametrium-Positive Patients with Stage Ib-Ilb Cervical Cancer 589 Treated by Radical Surgery and Adjuvant Therapy. Gynecol Oncol 590 [Internet]. 2007 [citado em: 13 de janeiro de 2022]; 105:757-761. 591 Disponível https://pubmed.ncbi.nlm.nih.gov/17433424/. 592 em: Doi: 10.1016/j.ygyno.2007.02.019. PMID: 17433424. 593
- 43. Kasamatsu T, Onda T, Sawada M, et al. Radical Hysterectomy for Figo 594 Stage I-IIb Adenocarcinoma of The Uterine Cervix. Br J Cancer 595 596 [Internet]. 2009 citado em: 08 de janeiro de 2023]; 100:1400-1405. Disponível em: https://doi.org/10.1038/sj.bjc.6605048. 597
- 44. Katanyoo K, Sanguanrungsirikul S, Manusirivithaya S. Comparison of 598 Treatment Outcomes Between Squamous Cell Carcinoma and 599 Adenocarcinoma in Locally Advanced Cervical Cancer. Gynecol 600 Oncol [Internet]. 2012 [citado em: 09 de janeiro de 2023]; 125:292-296. 601 https://pubmed.ncbi.nlm.nih.gov/22293041/. 602 Disponível em: Doi: 10.1016/j.ygyno.2012.01.034.PMID: 22293041. 603

45. Kang **Prognostic Significance** S, Wu J, Li J, et al. of 604 Clinicopathological Factors Influencing Overall Survival 605 and EventFree Survival of Patients with Cervical Cancer: A Systematic 606 Review and Meta-Analysis. Med Sci Monit [Internet]. 2022 [citado em: 607 2023]; 28:e934588. 10 de abril de Disponível 608 em: https://pubmed.ncbi.nlm.nih.gov/35260545/. Doi: 10.12659/MSM.934588. 609 PMID: 35260545; PMCID: PMC8919681. 610



Figure 1



Figure 2



Figure 3